Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23948508 | 0.86 | CA1 (0.40) | TRPV1HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL18536403 | 0.76 | MEN1 (0.42) | TRPV1MEN1MAPTKMT2AEPHX2 | |
| SCHEMBL22268975 | 0.76 | ACHE (0.35) | HSD17B10 | |
| SCHEMBL23920955 | 0.76 | ACHE (0.35) | HSD17B10 | |
| SCHEMBL27358463 | 0.74 | CETP (0.43) | FAAH | |
| SCHEMBL21556776 | 0.74 | CASP2 (0.45) | TRPV1FAAHCASP2 | |
| SCHEMBL23222256 | 0.74 | TSHR (0.43) | TRPV1HSD17B10MAPTKMT2A | |
| SCHEMBL25350370 | 0.72 | FAAH (0.77) | TRPV1FAAHDNM1EPHX2CASP2 | |
| SCHEMBL135555 | 0.72 | FAAH (0.77) | TRPV1FAAHDNM1EPHX2CASP2 | |
| SCHEMBL846255 | 0.72 | FAAH (0.77) | TRPV1FAAHDNM1EPHX2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | TRPV1 4865/4885HSD17B10 1278/4885MEN1 613/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | TRPV1 4865/4885HSD17B10 1278/4885MEN1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.